Beyond Protein A: Efficient Purification Strategies For Misbehaving mAbs

As biopharmaceutical pipelines expand beyond standard monoclonal antibodies, downstream processing must adapt to increasingly complex structures. Bispecific antibodies, Fc-fusion proteins, Fab fragments, and antibody–drug conjugates can introduce structural heterogeneity that conventional, Fc-focused purification platforms may struggle to resolve. Subdomain-specific variable domain heavy-chain-only (VHH) ligands offer a more precise approach by targeting distinct antibody regions. This selectivity can help improve purity, preserve molecular stability, and support process intensification for cGMP-compliant manufacturing.

Learn how tailored affinity strategies can address the purification challenges associated with next-generation antibody modalities and provide greater flexibility than traditional one-size-fits-all platforms.